Effect of subcutaneous lidocaine-hydroxypropyl-β-cyclodextrin (HP-β-CD) on quality of life in patients with post-COVID condition: a 36-week observational interrupted time series study.

Oostwouder CJ, Vos K, Lutke Schipholt IJ, Merkus MR, Telders T, van Deursen DFA, de Smit MB, van Eijk MD, Bontkes HJ, Bouwman FH, Wüst RCI, de Jong L, van Hulst M, Twisk JWR, van Kalken CK, Scholten-Peeters GGM

Open source

DOI
10.1016/j.eclinm.2025.103681
Published
2025 Dec
Container
EClinicalMedicine
Publisher
Not recorded
Open access
yes

Credibility signals

serious concern Score 10/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.1016/j.eclinm.2025.103681,
  title = {Effect of subcutaneous lidocaine-hydroxypropyl-β-cyclodextrin (HP-β-CD) on quality of life in patients with post-COVID condition: a 36-week observational interrupted time series study.},
  author = {Oostwouder CJ and Vos K and Lutke Schipholt IJ and Merkus MR and Telders T and van Deursen DFA and de Smit MB and van Eijk MD and Bontkes HJ and Bouwman FH and Wüst RCI and de Jong L and van Hulst M and Twisk JWR and van Kalken CK and Scholten-Peeters GGM},
  year = {2025},
  journal = {EClinicalMedicine},
  doi = {10.1016/j.eclinm.2025.103681},
  url = {https://doi.org/10.1016/j.eclinm.2025.103681}
}

RIS

TY  - JOUR
TI  - Effect of subcutaneous lidocaine-hydroxypropyl-β-cyclodextrin (HP-β-CD) on quality of life in patients with post-COVID condition: a 36-week observational interrupted time series study.
AU  - Oostwouder CJ
AU  - Vos K
AU  - Lutke Schipholt IJ
AU  - Merkus MR
AU  - Telders T
AU  - van Deursen DFA
AU  - de Smit MB
AU  - van Eijk MD
AU  - Bontkes HJ
AU  - Bouwman FH
AU  - Wüst RCI
AU  - de Jong L
AU  - van Hulst M
AU  - Twisk JWR
AU  - van Kalken CK
AU  - Scholten-Peeters GGM
PY  - 2025
JO  - EClinicalMedicine
DO  - 10.1016/j.eclinm.2025.103681
UR  - https://doi.org/10.1016/j.eclinm.2025.103681
ER  - 

APA

CJ, O., K, V., IJ, L. S., MR, M., T, T., DFA, V. D., MB, D. S., MD, V. E., HJ, B., FH, B., RCI, W., L, D. J., M, V. H., JWR, T., CK, V. K., & GGM, S. (2025). Effect of subcutaneous lidocaine-hydroxypropyl-β-cyclodextrin (HP-β-CD) on quality of life in patients with post-COVID condition: a 36-week observational interrupted time series study.. EClinicalMedicine. https://doi.org/10.1016/j.eclinm.2025.103681

Source records